North Carolina Biotechnology Center

The Center receives annual appropriations from the North Carolina General Assembly, supplemented by returns from its loan portfolio and equity positions in portfolio companies. Unlike a venture fund, it does not raise private LP capital. Its budget has historically ranged in the tens of millions annually, with allocations set by the state legislature as part of the economic development budget (public record).

Deal flow comes primarily through the technology transfer offices of Duke University, the University of North Carolina at Chapel Hill, and North Carolina State University — all of which hold board seats. The Center's six regional offices employ business development staff who prospect faculty founders and local entrepreneurs. NCBIO, the state life sciences trade association, serves as an additional referral channel for industry spinouts.

NCBiotech uses grants and convertible loans, not equity purchases. The Company Inception Loan program provides up to $250,000 for very early-stage companies. Strategic Growth Loans reach $500,000 for later-stage firms. Larger multi-year grants fund university research centers and workforce development programs. Loan repayments and equity conversions recycle back into the Center's pool for future awards.

A board of directors appointed by statute makes or delegates funding decisions. The board includes the chancellors of North Carolina's major research universities, executives from large biotech employers in the state, and public members appointed by the Governor and General Assembly. The President and CEO, Doug Edgeton, leads day-to-day operations and investment staff.

Through its loan programs, NCBiotech structures deals as convertible notes that convert to equity at the next qualified financing round. It does not lead priced equity rounds. This structure allows patient, state-sourced capital to fill pre-seed gaps without setting valuation terms for private investors.

Yes. The Center's legislative mandate requires that funded companies maintain a significant presence in North Carolina. Its mission is explicitly to grow the state's life sciences employment base and manufacturing footprint. It will fund companies relocating to the state when the move creates qualifying jobs.

The Center's mandated performance metrics are job creation, private capital leveraged, new company formation, and facilities investment attracted to North Carolina. Each grant and loan recipient reports employment and follow-on funding data. The public logic is that a growing, taxable biotech wage base and corporate property tax base produce the ROI for the state appropriation.